Mylan's move higher after FDA approval 'a little bit exaggerated,' says Wells Fargo analyst
October 04, 2017 at 17:37 PM EDT
While Mylan's FDA approval for its generic MS drug is a big win, simple math shows that investor reaction may be a bit too enthusiastic, David Maris said.
